Articles related to FDA

As of February 8, 2021, more than 31 million people in the U.S. had received at least one dose of the coronavirus vaccine, with 36 cases of immune thrombocytopenia (ITP) reported to the Vaccine Adverse Event Reporting System by the end of January. Is the onset of the condition related to the vaccines? The vaccines are considered safe overall, but what did the CDC and FDA have to say about it?

Despite the COVID-19 pandemic seemingly putting a hold on everything, approvals of new drugs have not waned. In fact, despite their high price tags – median prices ranged from $766 million to $2.8 billion – new drugs continue to roll out in 2021. Here are five new drugs approved this year that you may find useful in your clinical practice of medicine.

This drug was first approved in the US in the 1970s for anesthesia and pain relief, and last year, the FDA approved it for patients with major depression that are treatment resistant. If you said ketamine, you’re correct, and because more than 30% of patients are resistant to SSRIs, finding an effective treatment for major depressive disorder is challenging. Could this old drug be the answer?

A neurologist shares his experience receiving the first dose of the vaccine and what he felt during those 15 minutes of observation time. He had some reservations about the safety of the new vaccine, so was he about to become a statistic in the next FDA safety bulletin? Read on to discover the side effect — a feeling he hadn’t experienced in quite some time.

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL). Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.